Table 2.
Potential DAA/ART drug interactions
| DAA | ART | Change required |
|---|---|---|
| DCV | EFV | Increase DCV dose to 90 mg |
| DCV | NVP/ETR | Likely increase DCV dose to 90 mg (no data) |
| DCV | ATZ + EVG/COBI/FTC/TDF | Decrease DCV dose to 30 mg |
| LDV/SOF | TDF-based regimens | Use with caution, esp. if renal impairment |
| PROD | ART | Many drug interactions—do not use |
| ELB/GRZ | PIs | Contraindicated—do not use |
| ELB/GRZ | NNRTIs (except RLV) | Contraindicated—do not use |
| ELB/GRZ | EVG/COBI/FTC/TDF | Contraindicated—do not use |
| SOF/VEL | EFV | Contraindicated—do not use |
Data source: HepC Drug Interactions (http://www.hep-druginteractions.org)
ATZ atazanavir, COBI cobicistat, DCV daclatasvir, ELB elbasvir, ETR etravirine, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, GRZ grazoprevir, LDV ledipasvir, NNRTIs non-nuclease reverse-transcriptase inhibitors, NVP nevirapine, PIs protease inhibitors, PROD paritaprevir/ritonavir–ombitasvir and dasabuvir, RPV rilpivarine, SOF sofosbuvir, TDF tenofovir disoproxil fumarate